Mouse myeloma cell line NS0-derived recombinant human OBCAM Gly28-Asn322 Accession # Q14982
Detects human OBCAM on direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody does not cross‑react with recombinant human (rh) ALCAM, rhBCAM, rhEpCAM, rhNCAM, recombinant mouse (rm) MAdCAM, rmOCAM, or rmNCAM-L1.
Protein A or G purified from hybridoma culture supernatant
Test in a species/application not listed above to receive a full credit towards a future purchase.
OBCAM (Opioid-binding cell adhesion molecule, also known as OPCML) is a member of the IgLON family of cell adhesion molecules. All IgLONs are GPI-linked glycoproteins, contain three C2 type Ig-like domains, and are expressed in cerebral cortex and hippocampus (1, 2). The name IgLON derives from family membership in the Ig superfamily, and the first letters of the names of group’s molecules; LAMP, OBCAM, and Neurotrimin. Recently, membership in the group has been expanded by one with the addition of Kilon (Kindred of IgLON), and members of this group are now often referred to Diglons, based on the dimerizing nature of the IgLONs (1, 2). Human OBCAM is synthesized as a 345 amino acid (aa) preproprecursor that contains a 27 aa signal sequence, a 295 aa mature region, and a C‑terminal 23 aa prosegment (3). The prosegment is cleaved to generate the GPI-link. OBCAM varies in molecular weight, ranging from 46 kDa to 65 kDa (4 - 6). The difference is not due to alternate splicing but to differential glycosylation (6). Although it is not unusual for GPI-linked proteins to be solubilized, to date there is no evidence that OBCAM functions as a soluble molecule (1). Mature human OBCAM is 98%, 99%, and 98% aa identical to mature bovine, rat and mouse OBCAM, respectively. OBCAM has limited expression, occuring principally in telencephalon and ovarian epithelium (7, 8). In brain, it is found associated with dendrites and post-synaptic membranes, where it may maintain synaptic architecture (1, 5). In ovary, it has been suggested to be a tumor-suppressor factor (8). The receptor(s) for OBCAM appears to be other members of the IgLON family, and a dimer is the functional unit. While neurotrimin appears to function as both a homodimer and heterodimer, all other family members (including OBCAM) show a preference for heterodimerization. OBCAM forms strong trans (between cells) heterodimers with LAMP, and modest heterodimers with Neurotrimin. There is hardly any binding with itself. Kilon likely binds OBCAM, but this interaction is not well studied (1). OBCAM heterodimers apparently bind to almost all possible IgLON heterodimer combinations on other cells. In cis (same cell), OBCAM also binds to LAMP and Neurotrimin (2).
Miyata, S. et al. (2000) Neuroscience 117:645.
Reed, J. et al. (2004) J. Cell Sci. 117:3961.
Shark, K.B. and N.M. Lee (1995) Gene 155:213.
Wick, M.J. et al. (1996) Mol. Brain Res. 36:322.
Miyata, S. (2000) J. Comp. Neurol. 242:74.
Hachisuka, A. et al. (1996) Neurochem. Int. 28:373.
Miyata, S. et al. (2003) Brain Res. 979:129.
Sellar, G.C. et al. (2003) Nat. Genet. 34:337.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our OBCAM/OPCML Antibody (341723) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.